Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Nondrug
Route of Administration: Subcutaneous, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Austria | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Greece | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company Founding Year: 1896
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bangladesh, China, India, Sri Lanka, Uruguay
Active Clinical Trial Count: 13
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia|Asphyxia Neonatorum|Brain Diseases|Kidney Diseases|Kidney Failure, Chronic|Protein Deficiency
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06352138 |
ENCASE | P3 |
Not yet recruiting |
Anemia|Kidney Failure, Chronic |
2027-03-01 |
2024-08-20 |
Primary Endpoints|Start Date|Treatments |
|
NCT07025681 |
Janssen-Cilag | P3 |
Recruiting |
Protein Deficiency|Anemia |
2025-09-30 |
2025-06-18 |
Primary Endpoints|Treatments |
|
NCT05395195 |
EMBRACE | P3 |
Recruiting |
Brain Diseases|Asphyxia Neonatorum |
2024-12-01 |
2024-03-20 |
Primary Endpoints|Treatments |
|
CTR20213101 |
CTR20213101 | P2 |
Completed |
Kidney Diseases|Anemia |
2024-12-15 |
2025-07-27 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20213056 |
CTR20213056 | P3 |
Completed |
Kidney Diseases|Anemia |
2024-03-04 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20210357 |
CTR20210357 | P3 |
Completed |
Anemia|Kidney Diseases |
2023-04-27 |
2025-04-29 |
Patient Enrollment |
|
CTR20213265 |
CTR20213265 | P3 |
Completed |
Anemia |
2023-04-21 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232186 |
CTR20232186 | P3 |
Not yet recruiting |
Anemia |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT04954989 |
RUBI | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-12-01 |
50% |
2024-08-22 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
CTR20190234 |
CTR20190234 | P3 |
Active, not recruiting |
Anemia|Kidney Diseases |
None |
2025-04-29 |
||
CTR20131999 |
CTR20131999 | P1 |
Recruiting |
Anemia|Kidney Diseases |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20220540 |
CTR20220540 | P2 |
Completed |
Anemia |
2023-08-12 |
2025-04-29 |
||
CTR20192157 |
CTR20192157 | P2 |
Completed |
Anemia |
2023-03-02 |
2025-07-07 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/12/2026 |
News Article |
Geron Corporation Provides 2026 Financial Guidance |
|
01/13/2026 |
News Article |
Protein Therapeutics Market Set to Reach USD 740.07 Bn by 2034, Growing at 7.08% CAGR |
|
01/12/2026 |
News Article |
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook |
|
01/07/2026 |
News Article |
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs |